S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Pulse Biosciences Stock Forecast, Price & News

-0.01 (-0.65%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
3,753 shs
Average Volume
215,606 shs
Market Capitalization
$45.30 million
P/E Ratio
Dividend Yield
Price Target

Pulse Biosciences MarketRank™ Forecast

Analyst Rating
2.33 Rating Score
634.6% Upside
$11.17 Price Target
Short Interest
34.53% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.93mentions of Pulse Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.66) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.12 out of 5 stars

Medical Sector

342nd out of 1,428 stocks

Surgical & Medical Instruments Industry

44th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Pulse Biosciences logo

About Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

PLSE Stock News Headlines

Pulse Biosciences, Inc. Misses Q1 EPS by 6c
Pulse Biosciences, Inc. Announces Rights Offering
Pulse Biosciences, Inc. Misses Q4 EPS by 1c
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.42 million
Book Value
$1.20 per share


Free Float
Market Cap
$45.30 million

Pulse Biosciences Frequently Asked Questions

Should I buy or sell Pulse Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Pulse Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares.
View analyst ratings for Pulse Biosciences
or view top-rated stocks.

What is Pulse Biosciences' stock price forecast for 2022?

3 brokerages have issued 12-month price objectives for Pulse Biosciences' shares. Their PLSE stock forecasts range from $8.50 to $13.00. On average, they expect Pulse Biosciences' stock price to reach $11.17 in the next twelve months. This suggests a possible upside of 634.6% from the stock's current price.
View analysts' price targets for Pulse Biosciences
or view top-rated stocks among Wall Street analysts.

How has Pulse Biosciences' stock performed in 2022?

Pulse Biosciences' stock was trading at $14.81 at the beginning of 2022. Since then, PLSE shares have decreased by 89.7% and is now trading at $1.52.
View the best growth stocks for 2022 here

When is Pulse Biosciences' next earnings date?

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Pulse Biosciences

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) issued its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The firm earned $0.44 million during the quarter, compared to the consensus estimate of $0.70 million.
View Pulse Biosciences' earnings history

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the following people:
  • Mr. Darrin R. Uecker, Pres, CEO & Director (Age 56, Pay $511.42k)
  • Ms. Sandra A. Gardiner, Exec. VP of Fin. & Admin., CFO and Treasurer (Age 56, Pay $417.92k)
  • Mr. Mitchell E. Levinson, Chief Strategy Officer & Director (Age 62, Pay $449.02k)
  • Dr. Richard Nuccitelli Ph.D., Chief Science Officer
  • Mr. Kenneth B. Stratton Esq., J.D., Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Holly Hartman J.D., Ph.D., VP of Bus. Devel. & Corp. Strategy
  • Ms. Patty Perla, VP of HR
  • Mr. David Danitz, Sr. VP of Engineering
  • Mr. Kevin Danahy, Chief Commercial Officer (Age 51)

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences CEO Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among Pulse Biosciences' employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), (CGC), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $1.52.

How much money does Pulse Biosciences make?

Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $45.30 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does Pulse Biosciences have?

Pulse Biosciences employs 142 workers across the globe.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for Pulse Biosciences is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com.

This page (NASDAQ:PLSE) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.